Which has preferable valuation and earnings, INTS or GRI?

Intensity Therapeutics is trading at a lower price-to-earnings ratio than GRI Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Intensity Therapeutics N/A N/A -$11.61M -$3.57 N/A GRI Bio N/A N/A -$11.96M -$38.37 N/A

Is INTS or GRI more profitable?

Intensity Therapeutics' return on equity of -116.61% beat GRI Bio's return on equity. Company Net Margins Return on Equity Return on Assets Intensity Therapeutics N/A -116.61% -94.01% GRI Bio N/A -134.03% -106.83%

Which has stronger earnings & valuation, ADIL or GRI?

Adial Pharmaceuticals is trading at a lower price-to-earnings ratio than GRI Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Adial Pharmaceuticals N/A N/A -$7.98M -$14.73 N/A GRI Bio N/A N/A -$11.96M -$38.37 N/A

Is ADIL or GRI more profitable?

GRI Bio's return on equity of -134.03% beat Adial Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Adial Pharmaceuticals N/A -203.87% -512.41% GRI Bio N/A -134.03% -106.83%

Do analysts rate CABR or GRI?

GRI Bio has a consensus price target of $32.00, suggesting a potential upside of 1,046.95%. Given GRI Bio's stronger consensus rating and higher probable upside, analysts plainly believe GRI Bio is more favorable than Caring Brands. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Caring Brands 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 GRI Bio 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better earnings and valuation, CABR or GRI?

Caring Brands is trading at a lower price-to-earnings ratio than GRI Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Caring Brands N/A N/A -$6.28M -$0.74 N/A GRI Bio N/A N/A -$11.96M -$38.37 N/A

Is CABR or GRI more profitable?

GRI Bio's return on equity of -134.03% beat Caring Brands' return on equity. Company Net Margins Return on Equity Return on Assets Caring Brands N/A -1,153.12% -322.63% GRI Bio N/A -134.03% -106.83%

Is GRI or DARE more profitable?

GRI Bio has a net margin of 0.00% compared to Dare Bioscience's net margin of -803.80%. GRI Bio's return on equity of -134.03% beat Dare Bioscience's return on equity. Company Net Margins Return on Equity Return on Assets GRI Bio N/A -134.03% -106.83% Dare Bioscience -803.80% -748.30% -38.75%

Do analysts prefer GRI or KPRX?

GRI Bio presently has a consensus target price of $32.00, suggesting a potential upside of 1,046.95%. Given GRI Bio's stronger consensus rating and higher possible upside, analysts clearly believe GRI Bio is more favorable than Kiora Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GRI Bio 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Kiora Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is GRI or KPRX more profitable?

Kiora Pharmaceuticals' return on equity of -63.38% beat GRI Bio's return on equity. Company Net Margins Return on Equity Return on Assets GRI Bio N/A -134.03% -106.83% Kiora Pharmaceuticals N/A -63.38% -44.33%

GRI Bio (GRI) Competitors

$3.28 +0.99 (+43.14%)

As of 02:30 PM Eastern

Compare

GRI vs. INTS, ADIL, CABR, DARE, and KPRX

Should you buy GRI Bio stock or one of its competitors? GRI Bio's main competitors and comparable companies include Intensity Therapeutics (INTS), Adial Pharmaceuticals (ADIL), Caring Brands (CABR), Dare Bioscience (DARE), and Kiora Pharmaceuticals (KPRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does GRI Bio compare to Intensity Therapeutics?

Intensity Therapeutics (NASDAQ:INTS) and GRI Bio (NASDAQ:GRI) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, risk, analyst recommendations, profitability, valuation and earnings.

In the previous week, Intensity Therapeutics' average media sentiment score of 0.00 equaled GRI Bio'saverage media sentiment score.

Company	Overall Sentiment
Intensity Therapeutics	Neutral
GRI Bio	Neutral

Intensity Therapeutics has a beta of 2.76, suggesting that its stock price is 176% more volatile than the broader market. Comparatively, GRI Bio has a beta of -1.24, suggesting that its stock price is 224% less volatile than the broader market.

3.7% of Intensity Therapeutics shares are owned by institutional investors. Comparatively, 34.0% of GRI Bio shares are owned by institutional investors. 7.6% of Intensity Therapeutics shares are owned by company insiders. Comparatively, 8.7% of GRI Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Intensity Therapeutics presently has a consensus price target of $7.00, indicating a potential upside of 72.63%. GRI Bio has a consensus price target of $32.00, indicating a potential upside of 1,046.95%. Given GRI Bio's higher probable upside, analysts plainly believe GRI Bio is more favorable than Intensity Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intensity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
GRI Bio	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Intensity Therapeutics' return on equity of -116.61% beat GRI Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intensity Therapeutics	N/A	-116.61%	-94.01%
GRI Bio	N/A	-134.03%	-106.83%

Intensity Therapeutics is trading at a lower price-to-earnings ratio than GRI Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intensity Therapeutics	N/A	N/A	-$11.61M	-$3.57	N/A
GRI Bio	N/A	N/A	-$11.96M	-$38.37	N/A

Summary

Intensity Therapeutics beats GRI Bio on 8 of the 12 factors compared between the two stocks.

How does GRI Bio compare to Adial Pharmaceuticals?

Adial Pharmaceuticals (NASDAQ:ADIL) and GRI Bio (NASDAQ:GRI) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, institutional ownership, analyst recommendations, risk, earnings and profitability.

Adial Pharmaceuticals currently has a consensus price target of $15.63, suggesting a potential upside of 129.31%. GRI Bio has a consensus price target of $32.00, suggesting a potential upside of 1,046.95%. Given GRI Bio's higher probable upside, analysts plainly believe GRI Bio is more favorable than Adial Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adial Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
GRI Bio	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Adial Pharmaceuticals is trading at a lower price-to-earnings ratio than GRI Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adial Pharmaceuticals	N/A	N/A	-$7.98M	-$14.73	N/A
GRI Bio	N/A	N/A	-$11.96M	-$38.37	N/A

Adial Pharmaceuticals has a beta of 1.38, indicating that its share price is 38% more volatile than the broader market. Comparatively, GRI Bio has a beta of -1.24, indicating that its share price is 224% less volatile than the broader market.

16.4% of Adial Pharmaceuticals shares are held by institutional investors. Comparatively, 34.0% of GRI Bio shares are held by institutional investors. 8.0% of Adial Pharmaceuticals shares are held by company insiders. Comparatively, 8.7% of GRI Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Adial Pharmaceuticals' average media sentiment score of 0.00 equaled GRI Bio'saverage media sentiment score.

Company	Overall Sentiment
Adial Pharmaceuticals	Neutral
GRI Bio	Neutral

GRI Bio's return on equity of -134.03% beat Adial Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adial Pharmaceuticals	N/A	-203.87%	-512.41%
GRI Bio	N/A	-134.03%	-106.83%

Summary

GRI Bio beats Adial Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

How does GRI Bio compare to Caring Brands?

Caring Brands (NASDAQ:CABR) and GRI Bio (NASDAQ:GRI) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and dividends.

34.0% of GRI Bio shares are owned by institutional investors. 14.6% of Caring Brands shares are owned by company insiders. Comparatively, 8.7% of GRI Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

GRI Bio's return on equity of -134.03% beat Caring Brands' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Caring Brands	N/A	-1,153.12%	-322.63%
GRI Bio	N/A	-134.03%	-106.83%

GRI Bio has a consensus price target of $32.00, suggesting a potential upside of 1,046.95%. Given GRI Bio's stronger consensus rating and higher probable upside, analysts plainly believe GRI Bio is more favorable than Caring Brands.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Caring Brands	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
GRI Bio	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Caring Brands had 2 more articles in the media than GRI Bio. MarketBeat recorded 2 mentions for Caring Brands and 0 mentions for GRI Bio. Caring Brands' average media sentiment score of 0.83 beat GRI Bio's score of 0.00 indicating that Caring Brands is being referred to more favorably in the media.

Company	Overall Sentiment
Caring Brands	Positive
GRI Bio	Neutral

Caring Brands is trading at a lower price-to-earnings ratio than GRI Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Caring Brands	N/A	N/A	-$6.28M	-$0.74	N/A
GRI Bio	N/A	N/A	-$11.96M	-$38.37	N/A

Summary

GRI Bio beats Caring Brands on 7 of the 12 factors compared between the two stocks.

How does GRI Bio compare to Dare Bioscience?

GRI Bio (NASDAQ:GRI) and Dare Bioscience (NASDAQ:DARE) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, media sentiment, analyst recommendations and profitability.

GRI Bio has a net margin of 0.00% compared to Dare Bioscience's net margin of -803.80%. GRI Bio's return on equity of -134.03% beat Dare Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GRI Bio	N/A	-134.03%	-106.83%
Dare Bioscience	-803.80%	-748.30%	-38.75%

GRI Bio currently has a consensus price target of $32.00, suggesting a potential upside of 1,046.95%. Dare Bioscience has a consensus price target of $12.00, suggesting a potential upside of 1,500.00%. Given Dare Bioscience's stronger consensus rating and higher probable upside, analysts plainly believe Dare Bioscience is more favorable than GRI Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GRI Bio	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Dare Bioscience	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Dare Bioscience had 3 more articles in the media than GRI Bio. MarketBeat recorded 3 mentions for Dare Bioscience and 0 mentions for GRI Bio. GRI Bio's average media sentiment score of 0.00 beat Dare Bioscience's score of -0.18 indicating that GRI Bio is being referred to more favorably in the media.

Company	Overall Sentiment
GRI Bio	Neutral
Dare Bioscience	Neutral

GRI Bio has a beta of -1.24, indicating that its share price is 224% less volatile than the broader market. Comparatively, Dare Bioscience has a beta of 1.01, indicating that its share price is 1% more volatile than the broader market.

34.0% of GRI Bio shares are held by institutional investors. Comparatively, 6.7% of Dare Bioscience shares are held by institutional investors. 8.7% of GRI Bio shares are held by insiders. Comparatively, 4.1% of Dare Bioscience shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

GRI Bio has higher earnings, but lower revenue than Dare Bioscience. Dare Bioscience is trading at a lower price-to-earnings ratio than GRI Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GRI Bio	N/A	N/A	-$11.96M	-$38.37	N/A
Dare Bioscience	$1.03M	14.32	-$13.40M	-$0.70	N/A

Summary

Dare Bioscience beats GRI Bio on 8 of the 15 factors compared between the two stocks.

How does GRI Bio compare to Kiora Pharmaceuticals?

GRI Bio (NASDAQ:GRI) and Kiora Pharmaceuticals (NASDAQ:KPRX) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, dividends, risk, profitability, analyst recommendations, media sentiment, earnings and institutional ownership.

34.0% of GRI Bio shares are owned by institutional investors. Comparatively, 77.0% of Kiora Pharmaceuticals shares are owned by institutional investors. 8.7% of GRI Bio shares are owned by insiders. Comparatively, 0.5% of Kiora Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Kiora Pharmaceuticals has higher revenue and earnings than GRI Bio. Kiora Pharmaceuticals is trading at a lower price-to-earnings ratio than GRI Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GRI Bio	N/A	N/A	-$11.96M	-$38.37	N/A
Kiora Pharmaceuticals	$16.02M	0.72	-$10.84M	-$2.51	N/A

GRI Bio presently has a consensus target price of $32.00, suggesting a potential upside of 1,046.95%. Given GRI Bio's stronger consensus rating and higher possible upside, analysts clearly believe GRI Bio is more favorable than Kiora Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GRI Bio	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Kiora Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, GRI Bio's average media sentiment score of 0.00 equaled Kiora Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
GRI Bio	Neutral
Kiora Pharmaceuticals	Neutral

Kiora Pharmaceuticals' return on equity of -63.38% beat GRI Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GRI Bio	N/A	-134.03%	-106.83%
Kiora Pharmaceuticals	N/A	-63.38%	-44.33%

GRI Bio has a beta of -1.24, indicating that its share price is 224% less volatile than the broader market. Comparatively, Kiora Pharmaceuticals has a beta of -0.34, indicating that its share price is 134% less volatile than the broader market.

Summary

Kiora Pharmaceuticals beats GRI Bio on 7 of the 12 factors compared between the two stocks.

Get GRI Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GRI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GRI vs. The Competition

Export

Metric	GRI Bio	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$6.11M	$12.16B	$7.19B	$12.89B
Dividend Yield	N/A	2.59%	2.53%	8.57%
P/E Ratio	-0.07	787.21	272.97	25.41
Price / Sales	N/A	758.76	619.91	98.79
Price / Cash	N/A	94.80	77.82	52.27
Price / Book	0.59	12.51	12.87	6.18
Net Income	-$11.96M	$2.82B	$3.47B	$349.63M
7 Day Performance	45.31%	3.68%	1.11%	-0.02%
1 Month Performance	75.47%	6.59%	5.69%	0.85%
1 Year Performance	-93.36%	10.30%	25.57%	15.50%

GRI Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GRI GRI Bio	1.8187 of 5 stars	$3.28 +43.1%	$32.00 +876.2%	-94.4%	$6.70M	N/A	N/A	1	Gap Up High Trading Volume
INTS Intensity Therapeutics	2.28 of 5 stars	$4.89 +2.9%	$7.00 +43.1%	-40.5%	$15.51M	N/A	N/A	2,021	High Trading Volume
ADIL Adial Pharmaceuticals	2.7943 of 5 stars	$5.82 +7.8%	$15.63 +168.5%	-28.8%	$14.18M	N/A	N/A	20
CABR Caring Brands	0.4474 of 5 stars	$1.29 -4.8%	N/A	N/A	$14M	N/A	N/A	4	Gap Down
DARE Dare Bioscience	2.0895 of 5 stars	$0.82 +2.4%	$10.00 +1,118.5%	-65.4%	$12.26M	$1.03M	N/A	30

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GRI) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

GRI Bio (GRI) Competitors

GRI vs. INTS, ADIL, CABR, DARE, and KPRX

How does GRI Bio compare to Intensity Therapeutics?

Summary

How does GRI Bio compare to Adial Pharmaceuticals?

Summary

How does GRI Bio compare to Caring Brands?

Summary

How does GRI Bio compare to Dare Bioscience?

Summary

How does GRI Bio compare to Kiora Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRI vs. The Competition

GRI Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

GRI Bio (GRI) Competitors

GRI vs. INTS, ADIL, CABR, DARE, and KPRX

How does GRI Bio compare to Intensity Therapeutics?

Does the media refer more to INTS or GRI?

Which has more risk and volatility, INTS or GRI?

Do institutionals and insiders believe in INTS or GRI?

Do analysts rate INTS or GRI?

Is INTS or GRI more profitable?

Which has preferable valuation and earnings, INTS or GRI?

Summary

How does GRI Bio compare to Adial Pharmaceuticals?

Do analysts recommend ADIL or GRI?

Which has stronger earnings & valuation, ADIL or GRI?

Which has more risk & volatility, ADIL or GRI?

Do insiders and institutionals believe in ADIL or GRI?

Does the media refer more to ADIL or GRI?

Is ADIL or GRI more profitable?

Summary

How does GRI Bio compare to Caring Brands?

Do institutionals & insiders hold more shares of CABR or GRI?

Is CABR or GRI more profitable?

Do analysts rate CABR or GRI?

Does the media prefer CABR or GRI?

Which has better earnings and valuation, CABR or GRI?

Summary

How does GRI Bio compare to Dare Bioscience?

Is GRI or DARE more profitable?

Do analysts recommend GRI or DARE?

Does the media favor GRI or DARE?

Which has more volatility & risk, GRI or DARE?

Do insiders and institutionals hold more shares of GRI or DARE?

Which has stronger earnings and valuation, GRI or DARE?

Summary

How does GRI Bio compare to Kiora Pharmaceuticals?

Do insiders and institutionals hold more shares of GRI or KPRX?

Which has stronger valuation and earnings, GRI or KPRX?

Do analysts prefer GRI or KPRX?

Does the media favor GRI or KPRX?

Is GRI or KPRX more profitable?

Which has more risk & volatility, GRI or KPRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRI vs. The Competition

GRI Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools